Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers

Next Previous
Search
Trial Profile

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LP 003 Longbio Pharma (Primary)
  • Indications Allergic rhinitis; Asthma; Chronic urticaria
  • Focus Adverse reactions; First in man
  • Sponsors LongBio Pharma

    • Most Recent Events

    • 12 Mar 2024 Results (n=32) assessing Safety, Pharmacokinetics and Pharmacodynamics of LP-003 in healthy volunteers presented at the American Academy of Dermatology annual Meeting 2024
    • 12 Mar 2024 According to a LongBio Pharma Media Release, company nnounced the Phase I data of LP-003 (new generation of anti-IgE antibody) at the 2024 American Academy of Dermatology Association annual meeting (2024AAD).
    • 12 Mar 2024 Results presented in a LongBio Pharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top